Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin for Vascular Inflammation in Stable CAD
NCT05427084Phase 3Recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of canagliflozin in coronary artery disease (CAD), type 2 diabetes mellitus (T2DM), sponsored by University of Ottawa Heart Institute. Started Nov 2024; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
coronary artery disease (CAD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05427084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427084.